Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Biomarck Announces It Has Completed Enrollment in the Phase 2 Controlled Clinical Study in Non Small Cell Lung Cancer (NSCLC)


DURHAM, N.C., Nov. 28, 2018 /PRNewswire/ -- Biomarck Pharmaceuticals, Ltd today announced that it has completed enrollment in the Phase 2 study in NSCLC. This study compares standard of care, (pemetrexed/carboplatin. SOC) to SOC plus BIO-11006 in 60 patients with stage 4, NSCLC.  

Currently end stage NSCLC remains a terminal disease with a poor prognosis and quality of life. Immunotherapeutic agents have been shown to extend life but are associated with significant morbidity. While they are an important advancement there remains an opportunity to further enhance survival and quality of life in this patient group.

In Vivo studies have shown BIO-11006 can inhibit NSCLC metastases and reduce tumor size in several animal species. Those treated with BIO-11006 also did not lose weight over the treatment period. This study is intended to give an initial confirmation of these findings in a clinical setting.

About the Phase 2 study

This is a SOC controlled randomized, parallel group, clinical study evaluating BIO-11006 in addition to SOC in patients who have end stage NSCLC. The primary endpoint is progression free survival (PFS) at three months with secondary endpoints of response rate (RR), overall survival (OS) at 3 and 12 months. Body weight is also a clinical endpoint. Initial clinical results are expected in March 2019. For more information please visit https://clinicaltrials.gov ID number NCT 03472053

About BIO-11006

BIO-11006 is a novel patented peptide that inhibits the MARCKS protein. Phosphorylation of the MARCKS protein has been shown to stimulate cell division and movement. BIO-11006 has, in InVitro studies, shown activity against all solid tumors tested including lung, breast, colon and sarcoma. It is part of a portfolio of over 100 patented compounds owned by Biomarck.

About Biomarck

Biomarck Pharmaceuticals is a Durham, N.C. based biopharmaceutical company focused on the clinical development of its lead compound for the treatment of significant disease states such as ARDS and NSCLC. For additional information on Biomarck, please visit the Company's website at www.biomarck.com

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company's plans and expectations for BIO-11006, contain predictions, estimates and other forward looking statements. These forward looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risk related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks. 

Media/Investors
Mike Enright, Chief Financial Officer
844.424.6627
[email protected]

The information in the press release should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

SOURCE Biomarck Pharmaceuticals


These press releases may also interest you

at 04:00
Halfpricesoft.com offers a seamless and secure solution for in-house payroll processing with the l atest 2024 ezPaycheck YTD feature for those switching to the program, mid-year. The application is also combine d with features that have long...

at 04:00
U Power Limited (the "Company" or "U Power"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that the Company held an extraordinary general meeting of...

at 04:00
"The tourism data for Milan in 2023 reached an all-time high, and it's a success we must share among many stakeholders, both public and private, including the dense network of accommodation facilities in the city. We need virtuous examples like Hotel...

at 03:59
Timekettle, a fast-growing cross-language communication solutions innovator, has successfully wrapped up its #SpringTravelWithTimekettle campaign on Instagram. Running from March 18 to 24, Timekettle encouraged global travelers to share their...

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 03:44
Bitrue, a leading cryptocurrency exchange serving over 10 million users globally, announces a focus on user behavior analysis to further develop the utility of its native token, Bitrue Coin (BTR). "Understanding how our users interact with BTR is...



News published on and distributed by: